Maryland Caps Ozempic at $274, Saving State $5.8M Yearly

Maryland's drug affordability board just set a price ceiling on Ozempic, the widely prescribed type 2 diabetes treatment, capping what state and local governments will pay at $274 for a 30-day supply starting January 2027. The decision marks a watershed moment in the fight to make essential medications accessible to everyone who needs them.

The Maryland Prescription Drug Affordability Board operates like a state utility commission, bringing the same consumer protections used for electricity and water to prescription medications. This is only the second time the board has exercised this power, signaling a more aggressive approach to drug pricing reform.

The price cap will save an estimated $5.8 million annually for Maryland's state and local government health programs. Andrew York, the board's executive director, explained the new price was benchmarked against Medicare's maximum fair price, ensuring taxpayers aren't overcharged for critical medications.

The impact goes beyond just one drug. Maryland's board plans to expand its authority in 2028 to set upper payment limits on high-cost drugs for all state residents buying through commercial insurance markets, potentially helping hundreds of thousands more people afford their prescriptions.

For patients struggling with type 2 diabetes, this means predictable costs and fewer impossible choices between medication and other necessities. Ozempic has become essential for managing blood sugar levels in millions of Americans, but its high price has put it out of reach for many who need it most.

The Ripple Effect

Maryland's bold experiment could reshape how America handles prescription drug costs. As one of the first states to implement utility-style price regulations on pharmaceuticals, it's creating a roadmap other states are watching closely.

If the model proves successful, it could inspire similar boards nationwide, fundamentally changing the power dynamics between pharmaceutical companies and the patients who depend on their products. The approach treats healthcare access as a basic right rather than a luxury good.

Other states have already expressed interest in Maryland's approach, seeing it as a practical solution to a crisis that affects families across every demographic. When one state demonstrates that fair drug pricing is achievable without sacrificing access, it becomes harder to argue it can't work elsewhere.

The savings aren't just financial. When people can afford their diabetes medication, they avoid costly complications like heart disease, kidney failure, and vision loss that result from unmanaged blood sugar.

Maryland is proving that states don't have to wait for federal action to protect their residents from unsustainable drug prices.